|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we review CCL2/CCL12-CCR2, CCL3/4/5-CCR5, CCL15-CCR1, CX3CL1/CCL26-CX3CR1, CXCL5/2/1-CXCR2, CXCL8-CXCR1/2, CCL21-CCR7, CXCL13-CXCR5 signaling pathways, their role in MDSCs recruitment to tumor tissue, and their correlation with tumor development, metastasis and prognosis.
|
31835202 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dissecting the molecular and signaling events regulated by CXCL13 and how this chemokine dynamically controls the interaction between the cancer cell and the tumor microenvironment is key to identify novel effectors and therapeutic targets for cancer treatment.
|
31354634 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In particular, we identified significant targets related to tumor metabolism (Hexokinase 3), microenvironment (IDO1, CXCL13), cancer cells proliferation, migration and invasion (S100 proteins) or BCR signaling pathway (CD79B).
|
30696890 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The chemokine CXCL13 mediates recruitment of B cells to tumors and is essential for the formation of tertiary lymphoid structures (TLSs).
|
30872264 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We failed to find any association between the BALF content of progranulin or BCA-1 and the stage of tumor or prospectively assessed treatment response.
|
30357709 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The CXCL13 inhibitor reduced tumor volume and growth, and reduced the mRNA and protein expression levels of key members of the CXCR5/ERK signaling pathway: CXCL13, CXCR5 and ERK.
|
29844827 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High CXCL13 expression was associated with larger tumor diameter and shorter OS.
|
29085997 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of primary immune cell subsets revealed that IRF5 specifically recruits CXCR5(+) B and T cells to the tumor; CXCR5 is the receptor for CXCL13.
|
25533286 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CXCL13, an inflammatory factor in the microenvironment, plays a vital role in the progression of inflammatory diseases and tumors.
|
25476740 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry showed expression of follicular helper T cell markers (CD10, PD1, CXCL13, and BCL6) in tumor T cells.
|
25604350 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, tumor-infiltrated lymphocytes (TILs) accumulated in areas with expression of chemokines, particularly of CXCL13.
|
25433721 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A comparison of extensively versus minimally infiltrated tumors showed that CXCL13-producing CD4⁺ Tfh cells distinguish extensive immune infiltrates, principally located in tertiary lymphoid structure germinal centers.
|
23778140 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RNA was extracted from 321 formalin-fixed paraffin-embedded primary tumor tissue samples and quantitative reverse-transcriptase polymerase chain reaction was used to assess messenger RNA (mRNA) expression of CXCL12, CXCL13, and CXCR5; estrogen receptor; progesterone receptor (PgR); microtubule-associated protein tau and human epidermal growth factor receptor 2 (HER2).
|
22607768 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our data suggest that CXCL13 produced by stromal cells may contribute to the generation of an environment in which the malignant neuroblasts are retained, thus limiting the possible development of metastases in patients with SR tumor.
|
21642390 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our data implicate a functional role for CXCL13 in bone invasion and may be a potential therapeutic target to prevent osteolysis associated with OSCC tumors in vivo.
|
19816883 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
|
18781150 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of note, no CXCL13 reactivity was observed in a cohort of epithelial and mesenchymal neoplasms potentially mimicking FDC-S. FDC-S are commonly associated with a dense intratumoural inflammatory infiltrate and immunohistochemistry showed that these lymphocytes express the CXCL13 receptor CXCR5 and are mainly of mantle zone B-cell derivation (IgD+ and TCL1+).
|
18792075 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In PCNSL, expression of BCA-1 by malignant lymphocytes and vascular endothelium may influence tumor development and localization to CNS.
|
12393412 |
2003 |